JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

26.6 -4.08

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.43

Max

27.96

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.8M -57M
Pardavimai	35K 730K
Pelno marža	-7,753.425
Darbuotojai	186
EBITDA	-1.1M -63M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+77.81% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	390M 1.8B
Ankstesnė atidarymo kaina	30.68
Ankstesnė uždarymo kaina	26.6

Naujienos nuotaikos

By Acuity

100%

355 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-21 23:55; UTC

Karštos akcijos

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

2025-10-21 23:49; UTC

Uždarbis

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

2025-10-21 21:40; UTC

Uždarbis

Waste Connections 3Q Revenue Rises

2025-10-21 21:14; UTC

Uždarbis

Pagrindinės rinkos jėgos

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

2025-10-21 21:05; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

2025-10-21 20:57; UTC

Įsigijimai, susijungimai, perėmimai

DraftKings to Launch Prediction Markets Platform

2025-10-21 20:38; UTC

Uždarbis

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

2025-10-21 20:35; UTC

Uždarbis

Capital One 3Q Sales, Profit Jump

2025-10-21 20:32; UTC

Uždarbis

Texas Instruments 3Q Revenue Up on Growth Across End Markets

2025-10-21 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-21 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

2025-10-21 23:39; UTC

Rinkos pokalbiai

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

2025-10-21 23:36; UTC

Rinkos pokalbiai

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

2025-10-21 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Says This Forms Part of Capital Management Strategy

2025-10-21 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

2025-10-21 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

2025-10-21 21:09; UTC

Rinkos pokalbiai

Uždarbis

Netflix Creators Have Started Using AI in Production -- Market Talk

2025-10-21 20:58; UTC

Rinkos pokalbiai

Uždarbis

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

2025-10-21 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-21 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-10-21 20:43; UTC

Uždarbis

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

2025-10-21 20:41; UTC

Uždarbis

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

2025-10-21 20:33; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

2025-10-21 20:33; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

2025-10-21 20:31; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

2025-10-21 20:29; UTC

Uždarbis

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

77.81% į viršų

12 mėnesių prognozė

Vidutinis 49.2 USD 77.81%

Aukščiausias 67 USD

Žemiausias 25 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.